Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. The 3 PPAR isotypes, PPAR-α, PPAR-γ, and PPAR-δ, play a key role in the regulation of lipid and glucose metabolism. Obesity and the interrelated disorders of the metabolic syndrome have become a major worldwide health problem. In this review, we summarize the critical role of PPARs in regulating inflammation, lipoprotein metabolism, and glucose homeostasis and their potential implications for the treatment of obesity, diabetes, and atherosclerosis.

[1]  A. Butte,et al.  Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[3]  Xuhua Heng.  PPAR expression and function during vertebrate development , 2004 .

[4]  J. Fisher,et al.  Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. , 2002, American journal of physiology. Endocrinology and metabolism.

[5]  T. Okura,et al.  Vascular Inflammation Is Negatively Autoregulated by Interaction Between CCAAT/Enhancer-Binding Protein-&dgr; and Peroxisome Proliferator-Activated Receptor-&ggr; , 2002, Circulation research.

[6]  Philippe Froguel,et al.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.

[7]  L. Madsen,et al.  PPARa activators improve insulin sensitivity and reduce adiposity , 2000 .

[8]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2000. , 2002, JAMA.

[9]  P. Libby,et al.  PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis , 2002, Circulation research.

[10]  P. Drouin,et al.  Fenofibrate and human liver , 1983, Archives of Toxicology.

[11]  H. Lodish,et al.  Troglitazone Antagonizes Tumor Necrosis Factor-α-induced Reprogramming of Adipocyte Gene Expression by Inhibiting the Transcriptional Regulatory Functions of NF-κB* , 2003, Journal of Biological Chemistry.

[12]  M. Carroll,et al.  Overweight and obesity in the United States: prevalence and trends, 1960–1994 , 1998, International Journal of Obesity.

[13]  T. Meriden.  Progress with thiazolidinediones in the management of type 2 diabetes mellitus. , 2004, Clinical therapeutics.

[14]  Bruno Derudas,et al.  Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.

[15]  P. Libby,et al.  Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. , 2000, Journal of immunology.

[16]  M. Jaye,et al.  PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. , 2000, Nature medicine.

[17]  J. McGarry.  Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.

[18]  S. Haffner,et al.  Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  F. Colpaert,et al.  PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. , 2002, European journal of pharmacology.

[20]  Yun-ping Zhou,et al.  Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. , 1995, The Journal of clinical endocrinology and metabolism.

[21]  F. Hegardt,et al.  Control of Human Muscle-type Carnitine Palmitoyltransferase I Gene Transcription by Peroxisome Proliferator-activated Receptor* , 1998, The Journal of Biological Chemistry.

[22]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.

[23]  P. Drouin,et al.  Fenofibrate and human liver. Lack of proliferation of peroxisomes. , 1983, Archives of toxicology.

[24]  T. Willson,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. , 2000, The Journal of clinical investigation.

[25]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[26]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[27]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[28]  S. Hulley,et al.  Carcinogenicity of lipid-lowering drugs. , 1996, JAMA.

[29]  J. Gustafsson,et al.  Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Peach,et al.  Location and Regulation of Rat Angiotensinogen Messenger RNA , 1988, Hypertension.

[31]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[32]  E. Fleck,et al.  Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. , 2000, European journal of pharmacology.

[33]  B. Spiegelman,et al.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. , 1999, Molecular cell.

[34]  B. Spiegelman,et al.  Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. , 1995, Current opinion in genetics & development.

[35]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[36]  U. Smith,et al.  Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. , 2003, Biochemical and biophysical research communications.

[37]  W. Wahli,et al.  The PPARalpha-leukotriene B4 pathway to inflammation control. , 1996, Nature.

[38]  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[39]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[40]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[41]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[42]  M. Kobayashi,et al.  Improvement of Glucose Tolerance in NIDDM by Clofibrate Randomized Double-Blind Study , 1988, Diabetes Care.

[43]  K. Petersen,et al.  Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.

[44]  A. Tedgui,et al.  CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. , 2000, Circulation.

[45]  L. Mitnaul,et al.  Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. , 2005, Atherosclerosis.

[46]  G. Cooney,et al.  AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. , 2002, Diabetes.

[47]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[48]  Å. Sjöholm,et al.  Endothelial inflammation in insulin resistance , 2005, The Lancet.

[49]  W. Hsueh,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Retinoblastoma Phosphorylation and G1 → S Transition in Vascular Smooth Muscle Cells* , 2000, The Journal of Biological Chemistry.

[50]  K. Petersen,et al.  Cellular mechanism of insulin resistance: potential links with inflammation , 2003, International Journal of Obesity.

[51]  R. Evans,et al.  Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.

[52]  K. Kristiansen,et al.  Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. , 2001, The Journal of investigative dermatology.

[53]  R. Evans,et al.  Role for Peroxisome Proliferator-Activated Receptor &agr; in Oxidized Phospholipid–Induced Synthesis of Monocyte Chemotactic Protein-1 and Interleukin-8 by Endothelial Cells , 2000, Circulation research.

[54]  G. Cooney,et al.  Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin , 2004, Diabetologia.

[55]  J. Auwerx,et al.  Activation of PPARdelta alters lipid metabolism in db/db mice. , 2000, FEBS letters.

[56]  William A. Boisvert,et al.  Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ , 2003, Science.

[57]  E. Kraegen,et al.  Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. , 2004, Biochemical and biophysical research communications.

[58]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[59]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[60]  C. Packard,et al.  Effects of ciprofibrate on LDL metabolism in man. , 1994, Atherosclerosis.

[61]  R. Evans,et al.  Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[63]  D L Rothman,et al.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.

[64]  B. Jude,et al.  PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages , 2001 .

[65]  B. Spiegelman,et al.  Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. , 2003, The Journal of clinical investigation.

[66]  L. Weinehall,et al.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. , 1998, Circulation.

[67]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.

[68]  D. Moore,et al.  The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[69]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.

[70]  J. Auwerx,et al.  Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. , 1995, The Journal of clinical investigation.

[71]  G. Boden,et al.  Fatty acids and insulin resistance. , 1998, Diabetes care.

[72]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[73]  R. Eckel,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. , 2002, Circulation.

[74]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. , 2004, The Journal of clinical investigation.

[75]  R. Unger.  Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.

[76]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[77]  W. Koenig,et al.  Antidiabetic PPAR&ggr;-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease , 2003 .

[78]  W. Hsueh,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. , 2000, The Journal of biological chemistry.

[79]  P. Coward,et al.  Effects of peroxisome proliferator-activated receptor α/δ agonists on HDL-cholesterol in vervet monkeys Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M500002-JLR200 , 2005, Journal of Lipid Research.

[80]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[81]  J. Brunzell,et al.  Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. , 2002, The American journal of cardiology.

[82]  J. Auwerx,et al.  Activation of PPARδ alters lipid metabolism in db/db mice , 2000 .

[83]  R. Bergman,et al.  The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. , 1995, Annals of epidemiology.

[84]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[85]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[86]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[87]  J. Auwerx,et al.  Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[88]  B. Jude,et al.  PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. , 2001, Circulation.

[89]  S Kettle,et al.  Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced Hepatocarcinogenesis , 1994, Human & experimental toxicology.

[90]  O. Mcbride,et al.  cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. , 1993, Biochemistry.

[91]  Jiandie D. Lin,et al.  Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres , 2002, Nature.

[92]  M. Reitman,et al.  Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. , 2003, Diabetes.

[93]  W. Wahli,et al.  Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. , 2001, Endocrinology.

[94]  M. Reitman,et al.  WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. , 2002, The Journal of biological chemistry.

[95]  P. Libby,et al.  Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells1 , 2000, The Journal of Immunology.

[96]  Karsten Kristiansen,et al.  Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. , 2002 .

[97]  Jimmy D Bell,et al.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.

[98]  Rajnish A. Gupta,et al.  Activation of nuclear hormone receptor peroxisome proliferator–activated receptor-δ accelerates intestinal adenoma growth , 2004, Nature Medicine.

[99]  Y. Chao,et al.  Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice* , 2002, The Journal of Biological Chemistry.

[100]  Karsten Kristiansen,et al.  Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. , 2002, The Biochemical journal.

[101]  R. Evans,et al.  PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation , 2001, Nature Medicine.

[102]  T. Graham,et al.  The PPARδ agonist GW0742X reduces atherosclerosis in LDLR−/− mice , 2005 .

[103]  V. Laudet,et al.  The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* , 1998, The Journal of Biological Chemistry.

[104]  U. Boggi,et al.  Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. , 2002, Diabetes.

[105]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[106]  C. Glass,et al.  PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[107]  J. Peters,et al.  Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)* , 1998, The Journal of Biological Chemistry.

[108]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[109]  PPARs and the complex journey to obesity , 2004 .

[110]  J. S. St. Peter,et al.  A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. , 2002, Diabetes care.

[111]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[112]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[113]  R. Shulman,et al.  31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. , 1992, The Journal of clinical investigation.

[114]  B. Staels,et al.  Peroxisome proliferator-activated receptors in inflammation control. , 2001, The Journal of endocrinology.

[115]  T. Hashimoto,et al.  PEROXISOMAL β-OXIDATION AND PEROXISOME PROLIFERATOR–ACTIVATED RECEPTOR α: An Adaptive Metabolic System , 2001 .

[116]  F. Colpaert,et al.  PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells , 2002 .

[117]  P. J. Randle,et al.  THE GLUCOSE FATTY ACID CYCLE IN OBESITY AND MATURITY ONSET DIABETES MELLITUS , 1965, Annals of the New York Academy of Sciences.

[118]  W. Koenig,et al.  Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[119]  B. Sobel,et al.  Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. , 2000, Diabetes.

[120]  B. Spiegelman,et al.  A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor γ Inhibits Adipocyte Differentiation* , 2000, The Journal of Biological Chemistry.

[121]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[122]  R. Evans,et al.  Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. , 2003, Cell.

[123]  P. Libby,et al.  PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. , 1999, Circulation.

[124]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[125]  H. Motoshima,et al.  Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. , 2003, Diabetes.

[126]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[127]  Johan Auwerx,et al.  Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[128]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[129]  H. Lijnen.  Pleiotropic functions of plasminogen activator inhibitor‐1 , 2005, Journal of thrombosis and haemostasis : JTH.

[130]  G. Reach,et al.  PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. , 2001, Diabetes.

[131]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[132]  M. Reitman,et al.  WY14,643, a Peroxisome Proliferator-activated Receptor α (PPARα) Agonist, Improves Hepatic and Muscle Steatosis and Reverses Insulin Resistance in Lipoatrophic A-ZIP/F-1 Mice* , 2002, The Journal of Biological Chemistry.

[133]  C. Semenkovich,et al.  PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. , 2001, The Journal of clinical investigation.

[134]  F X Pi Sanyer.  THE OBESITY EPIDEMIC: PATHOPHYSIOLOGY AND CONSEQUENCES OF OBESITY , 2002 .

[135]  R. Coleman,et al.  AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. , 1999, The Biochemical journal.

[136]  Samy I McFarlane,et al.  Insulin resistance and cardiovascular disease. , 2001, The Journal of clinical endocrinology and metabolism.

[137]  M. Matsuda,et al.  Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. , 2005, Science.

[138]  Harvey F Lodish,et al.  Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. , 2003, Cytokine & growth factor reviews.

[139]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[140]  D. Leroith.  Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. , 2002, The American journal of medicine.

[141]  Christopher J. Lyon,et al.  Angiotensin II, PPAR-gamma and atherosclerosis. , 2004, Frontiers in bioscience : a journal and virtual library.

[142]  A. Takeshita,et al.  Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. , 2000, Circulation.

[143]  J Auwerx,et al.  Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*) , 1995, The Journal of Biological Chemistry.

[144]  S. Perrey,et al.  Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[145]  J. Després,et al.  A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. , 2002, Atherosclerosis.

[146]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[147]  Andrew C. Li,et al.  PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis Published, JLR Papers in Press, October 16, 2004. DOI 10.1194/jlr.R400010-JLR200 , 2004, Journal of Lipid Research.

[148]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[149]  T. Graham,et al.  The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. , 2005, Atherosclerosis.

[150]  Y. Ahn,et al.  Liver glucokinase can be activated by peroxisome proliferator-activated receptor-gamma. , 2004, Diabetes.

[151]  S. Luquet,et al.  Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. , 2004, Biochimie.

[152]  N. Ruderman,et al.  Lipid-Induced Insulin Resistance in Human Muscle Is Associated With Changes in Diacylglycerol, Protein Kinase C, and IκB-α , 2002 .

[153]  A. Muerhoff,et al.  The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. , 1992, The Journal of biological chemistry.

[154]  M. Cigolini,et al.  Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? , 1999, Atherosclerosis.

[155]  Daniel Metzger,et al.  Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice , 2001, The Journal of cell biology.

[156]  David Carling,et al.  The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[157]  A. Hamsten,et al.  Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). , 1997, The American journal of cardiology.

[158]  C. Harvengt,et al.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects , 2004, European Journal of Clinical Pharmacology.

[159]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[160]  Douglas L. Rothman,et al.  Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance , 2003, Science.

[161]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[162]  T Hashimoto,et al.  Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. , 2001, Annual review of nutrition.

[163]  W. Poston,et al.  Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials , 2002, International Journal of Obesity.

[164]  J. Shaw,et al.  Epidemiology of childhood type 2 diabetes in the developing world , 2004, Pediatric diabetes.

[165]  N. Ruderman,et al.  Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. , 2002, Diabetes.

[166]  C. Schmid,et al.  Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. , 2004, Archives of internal medicine.

[167]  M. Kurabayashi,et al.  PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. , 2002, Circulation research.

[168]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[169]  R. Evans,et al.  A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. , 2001, Molecular cell.

[170]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[171]  J. Sundell.  Obesity and diabetes as risk factors for coronary artery disease: from the epidemiological aspect to the initial vascular mechanisms , 2005, Diabetes, obesity & metabolism.

[172]  Philippe Froguel,et al.  Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation* , 2002, The Journal of Biological Chemistry.

[173]  J. Auwerx,et al.  Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[174]  P. Froguel,et al.  Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis* , 2003, The Journal of Biological Chemistry.

[175]  K. Murphy,et al.  A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. , 2002, Diabetes care.

[176]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[177]  V. Pasceri,et al.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. , 2000, Circulation.

[178]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[179]  T. Willson,et al.  The PPARs: From Orphan Receptors to Drug Discovery , 2000 .

[180]  Jiandie D. Lin,et al.  Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. , 2002, Nature.

[181]  G. Reach,et al.  PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance , 2001 .

[182]  P. Libby,et al.  PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells , 1999 .

[183]  J. Huttunen,et al.  The Helsinki Heart Study: central findings and clinical implications. , 1991, Annals of medicine.

[184]  E. Fleck,et al.  PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. , 1999, Journal of cardiovascular pharmacology.

[185]  W. Wahli,et al.  Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .

[186]  J. Borensztajn,et al.  The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. , 2003, The Biochemical journal.

[187]  G. Shulman,et al.  Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. , 2003, Diabetes.

[188]  C. Burant,et al.  Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.

[189]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[190]  Xianlin Han,et al.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. , 2002, The Journal of clinical investigation.

[191]  R. Shulman,et al.  Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[192]  G. Colditz,et al.  Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women , 1995, Annals of Internal Medicine.

[193]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[194]  Weimin He,et al.  Muscle-specific Pparg deletion causes insulin resistance , 2003, Nature Medicine.

[195]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[196]  S. Noji,et al.  Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. , 1998, Biochemical and biophysical research communications.

[197]  J. Peters,et al.  Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). , 1998, The Journal of biological chemistry.

[198]  G. Gil-Gómez,et al.  Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. , 1994, The Journal of biological chemistry.

[199]  R. Evans,et al.  PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. , 1998, Cell.

[200]  R. Unger,et al.  Fatty acid-induced β cell apoptosis: A link between obesity and diabetes , 1998 .

[201]  A. Tall,et al.  ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[202]  D. Freedman,et al.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. , 2002, The American journal of cardiology.

[203]  W. Hsueh,et al.  Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[204]  D. Kelly,et al.  A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[205]  H. Vosper,et al.  The Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages* , 2001, The Journal of Biological Chemistry.

[206]  K. Tolman,et al.  Hepatotoxicity of the thiazolidinediones. , 2003, Clinics in liver disease.

[207]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[208]  B. Staels,et al.  Peroxisome Proliferator-Activated Receptor &agr; Reduces Cholesterol Esterification in Macrophages , 2003, Circulation research.

[209]  J C Stanley,et al.  The glucose-fatty acid cycle. Relationship between glucose utilization in muscle, fatty acid oxidation in muscle and lipolysis in adipose tissue. , 1981, British journal of anaesthesia.

[210]  J. Peters,et al.  Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor α and γ Activators in a Tissue- and Inducer-specific Manner* , 1998, The Journal of Biological Chemistry.

[211]  A. Mahfoudi,et al.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[212]  Robert Elashoff,et al.  Coronary Vasomotor Abnormalities in Insulin-Resistant Individuals , 2004, Annals of Internal Medicine.

[213]  J. Peters,et al.  Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. , 1998, The Journal of biological chemistry.

[214]  K. Hosoda,et al.  Pathophysiological role of leptin in obesity-related hypertension. , 2000, The Journal of clinical investigation.

[215]  E. Kraegen,et al.  Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. , 2001, Biochemical Society transactions.

[216]  R. Unger,et al.  Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[217]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[218]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[219]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[220]  W. Wahli,et al.  Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. , 1999, The Journal of clinical investigation.

[221]  R. Unger,et al.  Lipotoxic diseases. , 2002, Annual review of medicine.

[222]  P. Geiger,et al.  Activation of p38 MAP kinase enhances sensitivity of muscle glucose transport to insulin. , 2005, American journal of physiology. Endocrinology and metabolism.

[223]  Dallas Jones,et al.  Emerging roles of PPARS in inflammation and immunity , 2002, Nature Reviews Immunology.

[224]  B. Seed,et al.  PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. , 1998, Nature.

[225]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[226]  G. Shulman,et al.  Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction , 2002, European journal of clinical investigation.

[227]  K. Petersen,et al.  Mechanisms of insulin resistance in humans and possible links with inflammation. , 2005, Hypertension.

[228]  P. Raskin,et al.  Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes , 2000, Diabetologia.

[229]  Margaret S. Wu,et al.  Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer ( PPAR g Agonist ) Action , 1998 .

[230]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[231]  K. Takeda,et al.  Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells , 2000 .

[232]  M. Prentki,et al.  AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome , 2004, Nature Reviews Drug Discovery.

[233]  J. Berger,et al.  Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. , 1998, Endocrinology.

[234]  P. Grimaldi,et al.  The roles of PPARs in adipocyte differentiation. , 2001, Progress in lipid research.

[235]  H. Lodish,et al.  Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. , 2003, The Journal of biological chemistry.

[236]  P. Arner.  Insulin resistance in type 2 diabetes: role of fatty acids , 2002, Diabetes/metabolism research and reviews.

[237]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[238]  H. Koshiyama,et al.  Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[239]  L. Chao,et al.  Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. , 2000, The Journal of clinical investigation.

[240]  S. Aizawa,et al.  PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. , 1999, Molecular cell.

[241]  Obesity in Adults,et al.  Identification, Evaluation, and Treatment of Overweight and Obesity , 2021, Obesity Prevention and Treatment.

[242]  M. Kurabayashi,et al.  PPARγ Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells , 2002 .

[243]  E. Fleck,et al.  Troglitazone inhibits angiotensin II‐induced extracellular signal‐regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells , 1999, FEBS letters.

[244]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[245]  M. Prentki,et al.  Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? , 2001, Diabetes.

[246]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. , 1998, Nature.

[247]  T. Rabelink,et al.  Thiazolidinediones and Blood Lipids in Type 2 Diabetes , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[248]  W. März,et al.  Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. , 2003, Diabetes care.

[249]  G. Lübben,et al.  Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus , 2003, Current medical research and opinion.

[250]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.